PR Newswire (Wed, 7:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
PR Newswire (Mar 19, 2013)
-
Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S.PR Newswire (Feb 19, 2013)
-
-
-
PR Newswire (Jan 8, 2013)
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Dec 5, 2012)
-
-
-
PR Newswire (Nov 8, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Look Beyond the Botched Buyout Process for Savient's ValueStone Fox Capital • Wed, Oct 27, 2010
-
-
-
-
-
What Moves Biotech Stocks? Ed Arce Has AnswersLife Sciences Report • Thu, Oct 18, 2012 -
-
-
-
-
-
-
-
-
-
-
-
-
-
4 Highly Liquid Biotech Stocks With Bullish Short TrendsKapitall • Thu, May 10, 2012
-
-
AstraZeneca Sprinting To Fix ItselfStephen Simpson • Thu, Apr 26, 2012
-
Savient Pharmaceuticals, Inc Q2 2010 Earnings Call TranscriptWed, Aug 4, 2010
-
Savient Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptSat, May 8, 2010
-
Savient Pharmaceuticals, Inc. Q1 2009 Earnings Call TranscriptFri, May 8, 2009
-
Savient Pharmaceuticals, Inc, Q4 Year Earnings Call TranscriptThu, Feb 26, 2009
-
Savient Pharmaceuticals, Inc. Q4 2007 Earning Call TranscriptWed, Mar 12, 2008
-
Savient Pharmaceuticals Q3 2007 Earnings Call TranscriptWed, Oct 31, 2007
-
PR Newswire (Wed, 7:00AM)
-
PR Newswire (Mar 19, 2013)
-
Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S.PR Newswire (Feb 19, 2013)
-
PR Newswire (Jan 8, 2013)
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Dec 5, 2012)
-
PR Newswire (Nov 8, 2012)
-
PR Newswire (Oct 19, 2012)
-
PR Newswire (Sep 26, 2012)
-
at MarketWatch.com (Sep 25, 2012)
-
PR Newswire (Sep 24, 2012)
-
at CNBC.com (Sep 19, 2012)
-
PR Newswire (Sep 5, 2012)
-
PR Newswire (Aug 27, 2012)
SVNT vs. ETF Alternatives
Company Description
We are a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase), or KRYSTEXXA, for the treatment of chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize... More
